KC-1321

CHOK1-LAG3-Cell-Line

×
21923
Home » CHOK1-LAG3-Cell-Line

Background of CHOK1-LAG3-Cell-Line

LAG3 (Lymphocyte-activation gene 3), also known as CD223, is an immune checkpoint receptor expressed on activated T cells, NK cells, and regulatory T cells. It belongs to the immunoglobulin superfamily and negatively regulates T cell activation, proliferation, and cytokine production by binding to MHC class II molecules. LAG3 is frequently upregulated in tumor-infiltrating lymphocytes, contributing to T cell exhaustion and immune evasion in various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Targeting LAG3 with monoclonal antibodies (e.g., relatlimab) has emerged as a promising cancer immunotherapy, often combined with PD-1 blockade.

Specifications

Catalog NumberKC-1321
Cell Line NameCHOK1-LAG3-Cell-Line
NCBI/UniProt Accession NumberNM_002286
Clone Number6#
Host Cell LineChinese hamster ovary CHO-K1 cell line
DescriptionStable CHOK1 cell line expressing exogenous human LAG3 gene.
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS+5µg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial-like
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 24 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

The CHOK1-LAG3 cell line was generated using a lentiviral vector expressing the human LAG3 sequence.

Characterization

Figure 1: Characterization of human LAG3 overexpression in the CHOK1-LAG3 stable clone using FACS.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Adam, Kieran et al. “Advances in LAG3 cancer immunotherapeutics.” Trends in cancer vol. 11,1 (2025): 37-48. doi:10.1016/j.trecan.2024.10.009
  2. Graydon, Colin G et al. “LAG3's Enigmatic Mechanism of Action.” Frontiers in immunology vol. 11 615317. 8 Jan. 2021, doi:10.3389/fimmu.2020.615317
  3. Munir, Amir Z et al. “Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.” Nature reviews. Cancer vol. 24,8 (2024): 540-553. doi:10.1038/s41568-024-00715-5
  4. Hu, Suiyuan et al. “LAG3 (CD223) and autoimmunity: Emerging evidence.” Journal of autoimmunity vol. 112 (2020): 102504. doi:10.1016/j.jaut.2020.102504

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.